Loading
A rare alpha-emitting halogen that can be attached to antibodies and small molecules like iodine, tested in leukaemia conditioning and brain and ovarian cancer.
Astatine-211 is an alpha emitter with a 7.2-hour half-life that behaves chemically like iodine, so it can label antibodies and small molecules by radiohalogenation. Its short range and high energy suit micrometastatic and disseminated disease; academic programmes in Gothenburg, Seattle and Japan have tested At-211 antibodies in ovarian cancer and as anti-CD45 conditioning before transplant, and At-211 PSMA and MABG agents are in early trials. Production requires a cyclotron with alpha beams, limiting supply to a few centres.
At-211 is produced by bombarding bismuth with alpha particles, labelled to a targeting molecule, and delivers high linear-energy-transfer alpha particles over a few cell diameters.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"Astatine-211 alpha therapy" OR ABSTRACT:"Astatine-211 alpha therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Astatine-211 alpha therapy, not a curated reading list.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Radioligand therapy (beta emitters), Prostate cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
Shares Targeted alpha therapy, Acute myeloid leukaemia, Prostate cancer.
Shares Radioligand therapy (beta emitters), Acute myeloid leukaemia, Ovarian cancer, Prostate cancer.